Apolipoprotein-A1 as a damage-associated molecular patterns protein in osteoarthritis: ex vivo and in vitro pro-inflammatory properties.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Apolipoprotein A-I/*metabolism ; Osteoarthritis/*metabolism; Adult ; Aged ; Aged, 80 and over ; Cells, Cultured ; Chondrocytes/immunology ; Chondrocytes/metabolism ; Female ; Humans ; Interleukin-6/genetics ; Interleukin-6/metabolism ; Lipopolysaccharides/pharmacology ; Male ; Matrix Metalloproteinase 1/metabolism ; Matrix Metalloproteinase 3/metabolism ; Middle Aged ; Osteoarthritis/immunology ; Primary Cell Culture ; Synovial Fluid/metabolism ; Toll-Like Receptor 4/metabolism ; Transcriptional Activation ; Young Adult

Osteoarthritis (OA) is associated with a local inflammatory process. Dyslipidemia is known to be an underlying cause for the development of OA. Therefore, lipid and inflammatory levels were quantified ex vivo in blood and synovial fluid of OA patients (n=29) and compared to those of rheumatoid arthritis (RA) patients (n=27) or healthy volunteers (HV) (n=35). The role of apolipoprotein A-I (ApoA1) was investigated in vitro on inflammatory parameters using human joint cells isolated from cartilage and synovial membrane obtained from OA patients after joint replacement. Cells were stimulated with ApoA1 in the presence or not of serum amyloid A (SAA) protein and/or lipoproteins (LDL and HDL) at physiological concentration observed in OA synovial fluid. In our ex vivo study, ApoA1, LDL-C and total cholesterol levels were strongly correlated to each other inside the OA joint cavity whereas same levels were not or weakly correlated to their corresponding serum levels. In OA synovial fluid, ApoA1 was not as strongly correlated to HDL as observed in OA serum or in RA synovial fluid, suggesting a dissociative level between ApoA1 and HDL in OA synovial fluid. In vitro, ApoA1 induced IL-6, MMP-1 and MMP-3 expression by primary chondrocytes and fibroblast-like synoviocytes through TLR4 receptor. HDL and LDL attenuated joint inflammatory response induced by ApoA1 and SAA in a ratio dependent manner. In conclusion, a dysregulated lipidic profile in the synovial fluid of OA patients was observed and was correlated with inflammatory parameters in the OA joint cavity. Pro-inflammatory properties of ApoA1 were confirmed in vitro.

Curr Cardiol Rep. 2014 Sep;16(9):512. (PMID: 25199216)
Clin Chim Acta. 2012 Jan 18;413(1-2):303-7. (PMID: 22037510)
Clin Chim Acta. 2008 Nov;397(1-2):42-7. (PMID: 18691566)
Curr Opin Rheumatol. 2010 Sep;22(5):533-7. (PMID: 20485173)
Arthritis Rheum. 2000 Mar;43(3):593-8. (PMID: 10728753)
Atherosclerosis. 2012 Jun;222(2):390-4. (PMID: 22456230)
Am J Manag Care. 2002 Oct;8(15 Suppl):S383-91. (PMID: 12416788)
Ann Rheum Dis. 2011 Mar;70(3):551-9. (PMID: 21216818)
Int J Cardiol. 2010 Jun 25;142(1):72-9. (PMID: 19171400)
J Lipid Res. 1996 Dec;37(12):2473-91. (PMID: 9017501)
Circ Res. 2014 Jan 3;114(1):171-82. (PMID: 24385510)
J Biol Chem. 2006 Aug 11;281(32):22597-604. (PMID: 16766531)
Prog Lipid Res. 2011 Apr;50(2):133-40. (PMID: 21115041)
Eur J Clin Invest. 2013 Nov;43(11):1129-39. (PMID: 24020867)
Arthritis Res Ther. 2009;11(6):R181. (PMID: 19961577)
Lab Invest. 2002 Dec;82(12):1661-72. (PMID: 12480916)
Metabolism. 2009 Oct;58(10):1393-9. (PMID: 19570555)
Scand J Rheumatol. 2014;43(6):498-502. (PMID: 25178483)
Atherosclerosis. 1993 Sep;102(2):131-46. (PMID: 7504491)
Expert Rev Cardiovasc Ther. 2012 Mar;10(3):353-61. (PMID: 22390807)
Pharmacol Rev. 2006 Sep;58(3):342-74. (PMID: 16968945)
Lab Invest. 2009 Jul;89(7):811-22. (PMID: 19434061)
J Biol Chem. 2013 Jul 19;288(29):21237-21252. (PMID: 23720750)
Anadolu Kardiyol Derg. 2013 Jun;13(4):306-14. (PMID: 23591583)
J Orthop Res. 2010 Aug;28(8):1033-9. (PMID: 20108316)
Arthritis Rheum. 1986 Aug;29(8):1039-49. (PMID: 3741515)
Clin Exp Rheumatol. 2009 Jan-Feb;27(1):79-83. (PMID: 19327233)
Arthritis Rheum. 1988 Mar;31(3):315-24. (PMID: 3358796)
Med J Aust. 2008 Mar 3;188(5):317. (PMID: 18312205)
Arterioscler Thromb Vasc Biol. 2011 Jun;31(6):1326-32. (PMID: 21474830)
Biochim Biophys Acta. 2013 Jun;1828(6):1503-10. (PMID: 23454085)
Scand J Rheumatol. 2004;33(5):293-9. (PMID: 15513676)
J Lipid Res. 2010 Apr;51(4):743-54. (PMID: 20061576)
Curr Opin Rheumatol. 2010 Sep;22(5):512-9. (PMID: 20592604)
Ann Rheum Dis. 2007 Jul;66(7):916-20. (PMID: 17314121)
Arthritis Rheum. 2008 Dec;58(12):3684-92. (PMID: 19035519)
Arthritis Rheum. 2006 Nov;54(11):3545-50. (PMID: 17075859)
Mol Pharmacol. 2011 Jan;79(1):34-41. (PMID: 20881006)
PLoS One. 2013 Jun 12;8(6):e66769. (PMID: 23776697)
Am J Pathol. 2001 Oct;159(4):1445-53. (PMID: 11583972)
Circulation. 2013 Sep 10;128(11):1256-67. (PMID: 24019446)

0 (Apolipoprotein A-I)
0 (IL6 protein, human)
0 (Interleukin-6)
0 (Lipopolysaccharides)
0 (TLR4 protein, human)
0 (Toll-Like Receptor 4)
EC 3.4.24.17 (MMP3 protein, human)
EC 3.4.24.17 (Matrix Metalloproteinase 3)
EC 3.4.24.7 (MMP1 protein, human)
EC 3.4.24.7 (Matrix Metalloproteinase 1)

Date Created: 20150408 Date Completed: 20160104 Latest Revision: 20240714

20240714

PMC4388661

10.1371/journal.pone.0122904

25849372